Heron Therapeutics Inc
Heron Therapeutics Inc (HRTX) Implied Volatility Current
HRTX's 30 day implied volatility is 707.77%, with an IV Rank of 86.51%. This is a high IV Rank versus the past year, meaning Heron Therapeutics Inc options are relatively expensive and currently favor sellers. HRTX's 30 day historical volatility sits at 118.18%, which means implied volatility is running 589.59 points above historical volatility, as of Nov 19, 2026.
Read more
Tracking HRTX implied volatility helps you spot when Heron Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When HRTX IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor HRTX implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking HRTX IV rank helps you see whether HRTX's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Implied Volatility
IV is highly elevated. Premiums are expensive, strongly favoring sellers.
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →